|
1
|
Brambilla E, Travis WD, Colby TV, Corrin B
and Shimosato Y: The new World Health Organization classification
of lung tumours. Eur Respir J. 18:1059–1068. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mendelsohn J and Baselga J: The EGF
receptor family as targets for cancer therapy. Oncogene.
19:6550–6565. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brognard J, Clark AS, Ni Y and Dennis PA:
Akt/protein kinase B is constitutively active in non-small cell
lung cancer cells and promotes cellular survival and resistance to
chemotherapy and radiation. Cancer Res. 61:3986–3997.
2001.PubMed/NCBI
|
|
4
|
Mukohara T, Kudoh S, Yamauchi S, et al:
Expression of epidermal growth factor receptor (EGFR) and
downstream-activated peptides in surgically excised non-small cell
lung cancer (NSCLC). Lung Cancer. 41:123–130. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
D’Amico TA, Massey M, Herndon JE, Moore MB
and Harpole DH: A biologic risk model for stage I lung cancer:
immunohistochemical analysis of 408 patients with the use of ten
molecular markers. J Thorac Cardiovasc Surg. 117:736–743.
1999.PubMed/NCBI
|
|
6
|
Shiba M, Kohno H, Kakizawa K, et al: Ki-67
immunostaining and other prognostic factors including tobacco
smoking in patients with resected nonsmall cell lung carcinoma.
Cancer. 89:1457–1465. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lloyd RV, Erickson LA, Jin L, Kulig E,
Qian X, Cheville JC and Scheithauer BW: p27kip1: a multifunctional
cyclin-dependent kinase inhibitor with prognostic significance in
human cancers. Am J Pathol. 154:313–323. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hayashi H, Ogawa N, Ishiwa N, Yazawa T,
Inayama Y, Ito T and Kitamura H: High cyclin E and low p27/Kip1
expressions are potentially poor prognostic factors in lung
adenocarcinoma patients. Lung Cancer. 34:59–65. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hommura F, Dosaka-Akita H, Mishina T, et
al: Prognostic significance of p27KIP1 protein and ki-67 growth
fraction in non-small cell lung cancers. Clin Cancer Res.
6:4073–4081. 2000.PubMed/NCBI
|
|
10
|
Thim L and May FE: Structure of mammalian
trefoil factors and functional insights. Cell Mol Life Sci.
62:2956–2973. 2005.PubMed/NCBI
|
|
11
|
Taupin D and Podolsky DK: Trefoil factors:
initiators of mucosal healing. Nat Rev Mol Cell Biol. 4:721–732.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bossenmeyer-Pourié C, Kannan R, Ribieras
S, et al: The trefoil factor 1 participates in gastrointestinal
cell differentiation by delaying G1-S phase transition and reducing
apoptosis. J Cell Biol. 157:761–770. 2002.PubMed/NCBI
|
|
13
|
Chan MW, Chan VY, Leung WK, Chan KK, To
KF, Sung JJ and Chan FK: Anti-sense trefoil factor family-3
(intestinal trefoil factor) inhibits cell growth and induces
chemosensitivity to adriamycin in human gastric cancer cells. Life
Sci. 76:2581–2592. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yio X, Diamond M, Zhang JY, Weinstein H,
Wang LH, Werther L and Itzkowitz S: Trefoil factor family-1
mutations enhance gastric cancer cell invasion through distinct
signaling pathways. Gastroenterology. 130:1696–1706. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hoosein NM, Thim L, Jørgensen KH and
Brattain MG: Growth stimulatory effect of pancreatic spasmolytic
polypeptide on cultured colon and breast tumor cells. FEBS Lett.
247:303–306. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Emami S, Rodrigues S, Rodrigue CM, et al:
Trefoil factor family (TFF) peptides and cancer progression.
Peptides. 25:885–898. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yio X, Zhang JY, Babyatsky M, et al:
Trefoil factor family-3 is associated with aggressive behavior of
colon cancer cells. Clin Exp Metastasis. 22:157–165. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chan VY, Chan MW, Leung WK, Leung PS, Sung
JJ and Chan FK: Intestinal trefoil factor promotes invasion in
non-tumorigenic Rat-2 fibroblast cell. Regul Pept. 127:87–94. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Graness A, Chwieralski CE, Reinhold D,
Thim L and Hoffmann W: Protein kinase C and ERK activation are
required for TFF-peptide-stimulated bronchial epithelial cell
migration and tumor necrosis factor-alpha-induced interleukin-6
(IL-6) and IL-8 secretion. J Biol Chem. 277:18440–18446. 2002.
View Article : Google Scholar
|
|
20
|
Rodrigues S, Van Aken E, Van Bocxlaer S,
et al: Trefoil peptides as proangiogenic factors in vivo and in
vitro: implication of cyclooxygenase-2 and EGF receptor signaling.
FASEB J. 17:7–16. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dhar DK, Wang TC, Tabara H, et al:
Expression of trefoil factor family members correlates with patient
prognosis and neoangiogenesis. Clin Cancer Res. 11:6472–6478. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Regalo G, Wright NA and Machado JC:
Trefoil factors: from ulceration to neoplasia. Cell Mol Life Sci.
62:2910–2915. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
May FE and Westley BR: Expression of human
intestinal trefoil factor in malignant cells and its regulation by
oestrogen in breast cancer cells. J Pathol. 182:404–413. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Henry JA, Nicholson S, Hennessy C, Lennard
TW, May FE and Westley BR: Expression of the oestrogen regulated
pNR-2 mRNA in human breast cancer: relation to oestrogen receptor
mRNA levels and response to tamoxifen therapy. Br J Cancer.
61:32–38. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
May FE and Westley BR: Trefoil proteins:
their role in normal and malignant cells. J Pathol. 183:4–7. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
West M, Blanchette C, Dressman H, et al:
Predicting the clinical status of human breast cancer by using gene
expression profiles. Proc Natl Acad Sci USA. 98:11462–11467. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Speiser P, Stolzlechner J, Haider K, et
al: pS2 protein status fails to be an independent prognostic factor
in an average breast cancer population. Anticancer Res.
14:2125–2130. 1994.
|
|
28
|
Gillesby BE and Zacharewski TR: pS2 (TFF1)
levels in human breast cancer tumor samples: correlation with
clinical and histological prognostic markers. Breast Cancer Res
Treat. 56:253–265. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tozlu S, Girault I, Vacher S, et al:
Identification of novel genes that co-cluster with estrogen
receptor alpha in breast tumor biopsy specimens, using a
large-scale real-time reverse transcription-PCR approach. Endocr
Relat Cancer. 13:1109–1120. 2006. View Article : Google Scholar
|
|
30
|
Doane AS, Danso M, Lal P, Donaton M, Zhang
L, Hudis C and Gerald WL: An estrogen receptor-negative breast
cancer subset characterized by a hormonally regulated
transcriptional program and response to androgen. Oncogene.
25:3994–4008. 2006. View Article : Google Scholar
|
|
31
|
Smid M, Wang Y, Klijn JG, et al: Genes
associated with breast cancer metastatic to bone. J Clin Oncol.
24:2261–2267. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bosma AJ, Weigelt B, Lambrechts AC, et al:
Detection of circulating breast tumor cells by differential
expression of marker genes. Clin Cancer Res. 8:1871–1877.
2002.PubMed/NCBI
|
|
33
|
Weigelt B, Bosma AJ, Hart AA, Rodenhuis S
and van ‘t Veer LJ: Marker genes for circulating tumour cells
predict survival in metastasized breast cancer patients. Br J
Cancer. 88:1091–1094. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ren JL, Luo JY, Lu YP, Wang L and Shi HX:
Molecular forms of trefoil factor 1 in normal gastric mucosa and
its expression in normal and abnormal gastric tissues. World J
Gastroenterol. 12:7361–7364. 2006.PubMed/NCBI
|
|
35
|
Milne AN, Carvalho R, Morsink FM, Musler
AR, de Leng WW, Ristimäki A and Offerhaus GJ: Early-onset gastric
cancers have a different molecular expression profile than
conventional gastric cancers. Mod Pathol. 19:564–572. 2006.
View Article : Google Scholar
|
|
36
|
Sonoda H, Yamamoto K, Kushima R, Yamamoto
H, Naitoh H, Okabe H and Tani T: Detection of lymph node
micrometastasis in pN0 early gastric cancer: Efficacy of duplex
RT-PCR with MUC2 and TFF1 in mucosal cancer. Oncol Rep. 16:411–416.
2006.PubMed/NCBI
|
|
37
|
Suárez C, Vizoso F, Rodríguez JC, et al:
Prognostic significance of cytosolic pS2 protein content in gastric
cancer. Int J Biol Markers. 16:37–44. 2001.PubMed/NCBI
|
|
38
|
Mori K, Aoyagi K, Ueda T, et al: Highly
specific marker genes for detecting minimal gastric cancer cells in
cytology negative peritoneal washings. Biochem Biophys Res Commun.
313:931–937. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tuna B, Sökmen S, Sarioğlu S, Füzün M,
Küpelioğlu A and Ellidokuz H: PS2 and HSP70 expression in rectal
adenocarcinomas: an immunohistochemical investigation of 45 cases.
Appl Immunohistochem Mol Morphol. 14:31–36. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Taupin D, Ooi K, Yeomans N and Giraud A:
Conserved expression of intestinal trefoil factor in the human
colonic adenoma-carcinoma sequence. Lab Invest. 75:25–32.
1996.PubMed/NCBI
|
|
41
|
Welsh JB, Sapinoso LM, Su AI, et al:
Analysis of gene expression identifies candidate markers and
pharmacological targets in prostate cancer. Cancer Res.
61:5974–5978. 2001.PubMed/NCBI
|
|
42
|
Luo J, Duggan DJ, Chen Y, et al: Human
prostate cancer and benign prostatic hyperplasia: molecular
dissection by gene expression profiling. Cancer Res. 61:4683–4688.
2001.PubMed/NCBI
|
|
43
|
Vestergaard EM, Borre M, Poulsen SS, Nexø
E and Tørring N: Plasma levels of trefoil factors are increased in
patients with advanced prostate cancer. Clin Cancer Res.
12:807–812. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Buache E, Etique N, Alpy F, et al:
Deficiency in trefoil factor 1 (TFF1) increases tumorigenicity of
human breast cancer cells and mammary tumor development in
TFF1-knockout mice. Oncogene. 30:3261–3273. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shen J, Liu J, Xie Y, Diwan BA and Waalkes
MP: Fetal onset of aberrant gene expression relevant to pulmonary
carcinogenesis in lung adenocarcinoma development induced by in
utero arsenic exposure. Toxicol Sci. 95:313–320. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mathelin C, Tomasetto C and Rio MC:
Trefoil factor 1 (pS2/TFF1), a peptide with numerous functions.
Bull Cancer. 92:773–781. 2005.PubMed/NCBI
|
|
47
|
Liu S, Stromberg A, Tai HH and Moscow JA:
Thiamine transporter gene expression and exogenous thiamine
modulate the expression of genes involved in drug and prostaglandin
metabolism in breast cancer cells. Mol Cancer Res. 2:477–487.
2004.PubMed/NCBI
|
|
48
|
dos Santos Silva E, Ulrich M, Döring G,
Botzenhart K and Gött P: Trefoil factor family domain peptides in
the human respiratory tract. J Pathol. 190:133–142. 2000.PubMed/NCBI
|
|
49
|
Higashiyama M, Doi O, Kodama K, Yokuchi H,
Inaji H and Tateishi R: Estimation of serum level of pS2 protein in
patients with lung adenocarcinoma. Anticancer Res. 16:2351–2355.
1996.PubMed/NCBI
|
|
50
|
Higashiyama M, Doi O, Kodama K, Yokouchi
H, Inaji H, Nakamori S and Tateishi R: Prognostic significance of
pS2 protein expression in pulmonary adenocarcinoma. Eur J Cancer.
30:792–797. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kosriwong K, Menheniott TR, Giraud AS,
Jearanaikoon P, Sripa B and Limpaiboon T: Trefoil factors: tumor
progression markers and mitogens via EGFR/MAPK activation in
cholangiocarcinoma. World J Gastroenterol. 17:1631–1641. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Qu Y, Yang Y, Liu B and Xiao W:
Comparative proteomic profiling identified sorcin being associated
with gemcitabine resistance in non-small cell lung cancer. Med
Oncol. 27:1303–1308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Madsen J, Nielsen O, Tornøe I, Thim L and
Holmskov U: Tissue localization of human trefoil factor 1, 2 and 3.
J Histochem Cytochem. 55:505–513. 2007. View Article : Google Scholar
|
|
54
|
Aikou S, Ohmoto Y, Gunji T, et al: Tests
for serum levels of trefoil factor family proteins can improve
gastric cancer screening. Gastroenterology. 141:837–845. 2011.
View Article : Google Scholar : PubMed/NCBI
|
